Yadlapalli will succeed Bikash Chatterjee, who will remain with the organisation as President and Chief Science Officer
The Board of Directors of Pharmatech Associates announced the appointment of Sireesha Yadlapalli as chief executive officer, effective June 5, 2023. Yadlapalli will succeed Bikash Chatterjee, who will remain with the organisation as President and Chief Science Officer.
Yadlapalli brings industry and regulatory experience to Pharmatech gained during her over a 20-year career in the biopharmaceutical industry in positions in finance, business development, strategic marketing, and regulatory affairs. Before taking on her new role, Yadlapalli served on the organization’s Board of Directors and as Vice President, International Government and Regulatory Affairs at US Pharmacopeia (USP). While at USP, she served as the Regional Director of South Asia. Before joining USP, Sireesha held senior-level positions at Dr Reddy’s Laboratories, Valeant Pharmaceuticals International, and Johnson & Johnson.
“On behalf of the Board, I am thrilled to welcome Sireesha as she directs the growth trajectory of Pharmatech to support manufacturers to efficiently bring life-saving medicines to market,” said Emily Kaine, MD, Chairperson of the Board of Directors, Pharmatech Associates and senior vice president, USP’s Global Health and Manufacturing Services. “Sireesha is a strong leader and has brought global regulatory, market insights, and business understanding to the board of directors which has been extremely valuable.”
Pharmatech, a wholly owned subsidiary of USP, is poised to expand significantly to support the US and globally-based drug sponsors and manufacturers with development, quality, and regulatory compliance consulting services to supply quality medicines to all major markets. Pharmatech’s collaborative efforts with USP and other healthcare stakeholders help lower barriers to the adoption of Advanced Manufacturing Technologies such as pharmaceutical continuous manufacturing to bring more quality products to market.
As a partner with deep domain expertise ranging from small molecules to cell and gene therapy, biologics, and advanced manufacturing technologies, Pharmatech empowers clients to address complex challenges in the development of quality medicines. Services include regulatory strategy, compliance, and remediation to address manufacturing quality, CMC, process, equipment and facility development, analytical method qualification; and advanced manufacturing strategy, planning and control services.
“To remain competitive requires a mix of technical knowledge, practical business experience, broad regulatory compliance understanding, and a culture of precise execution,” said Ronald T Piervincenzi, USP’s CEO. “Yadlapalli brings outstanding talent, a wealth of knowledge and leadership experience in pharmaceutical and biologics industries across the US and international markets, that she’ll put to use to grow Pharmatech as a leading consultancy to advance the supply of quality medicines.”